Peter Smith

Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Pete received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.